Public Citizen Files Lawsuit To Get FDA to Add Impulse Control Warning Added To Requip, Similar Parkinson’s Disease Drugs
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Abilify Pathological Gambling Problems Withheld from Medical Community, Lawsuit Alleges January 27, 2016 Irvin Jackson Add Your Comments According to allegations raised in a recently filed product liability lawsuit, Bristol-Myers Squibb and Otsuka Pharmaceutical Co. have withheld information from consumers and the medical community about the risk of pathological gambling problems on Abilify, which is one of the top-selling brand name medications on the market. The complaint (PDF) was filed by Thomas Leland in the U.S. District Court for the Western District of Missouri on January 20, indicating that after he began using the atypical antipsychotic medication he suffered substantial gambling losses, lost his employment, severely damage to his financial stability and suffered other mental and physical losses. Leland indicates that he was prescribed Abilify in March 2013, and began compulsively gambling shortly thereafter. After he stopped taking the medication in about August 2015, Leland states that his pathological gambling stopped a short time later. Learn More About Abilify Lawsuits Side Effects of Abilify May Increase the Risk of Compulsive Gambling, Shopping and Other Addictive Behaviors Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Abilify Lawsuits Side Effects of Abilify May Increase the Risk of Compulsive Gambling, Shopping and Other Addictive Behaviors Learn More SEE IF YOU QUALIFY FOR COMPENSATION The lawsuit alleges that side effects of Abilify caused him to engage in the pathological gambling behavior, adversely impacting his brain. Abilify (ariprazole) is typically prescribed for treatment of schizophrenia, bipolar disorder and as an adjunct for depression and autism spectrum disorders, generating annual sales of more than $6 billion per year, making it the top selling brand name drug on the market in 2013. In about November 2012, European drug regulators required Abilify pathological gambling warnings, adding information to the label about reports of users engaging in uncontrollable gambling activities and recommending that patients should be monitored carefully. However, similar warnings were not provided to doctors in the United States. Similar warnings about the link between Abilify and gambling were provided to the Canadian medical community in November 2015, after drug regulators identified cases where users began compulsive gambling or hypersexuality behavior. “Despite these warnings and advisories in Europe and Canada – for the same drug sold to patients in the United States – the labeling for Abilify in the United States contains no mention that pathological gambling has been reported in patients prescribed Abilify,” according to the complaint filed by Leland. In an October 2014 study published in the medical journal JAMA Internal Medicine, researchers found evidencethat a class of drugs known as dopamine receptor agonists, often used to treat Parkinson’s disease, were linked to gambling and impulse control problems. However, the researchers also saw the same behavioral problems associated with the use of Abilify, which is a partial dopamine agonist. Leland notes that Bristol-Myers Squibb and Otsuka have been aware for years of case reports linking Abilify to pathological gambling behaviors, including several case reports that demonstrate strong evidence of a causal connection through “challenge, de-challenge and re-challenge.” This term is used to describe a situation where an adverse event begins when use of a drug starts (challenge), ceases when the drug is no longer used (de-challenge), but returns when the medication is taken again (re-challenge). “Despite evidence that Abilify causes compulsive behaviors like pathological gambling and calls from the medical community to conduct further research and warn patients about this possible effect of Abilify, Defendants have either failed to investigate or conduct any studies on the compulsive behavior side effects of Abilify or failed to make public the results of any studies or investigations that they might have done,” the lawsuit states. The complaint indicates that an analysis of the FDA Adverse Event Report System has demonstrated an escalating number of reports involving Abilify compulsivity, inclyding at least 29 reports of pathological gambling with Abilify in 2014. Addictive gambling on Abilify can have a severe impact on users, causing substantial financial losses and behavior that can destroy families, reputations and cause irreparable damage to an individuals quality of life. Leland’s case comes a growing number of similar Abilify gambling lawsuits are being pursued by other users, alleging that plaintiffs may have avoided devastating consequences on their financial situation and quality of life if users and the medical community had been warned to be on the look out for signs of compulsive gambling or other pathological behaviors while using the drug. Tags: Abilify, Antidepressant, Bristol Myers Squibb, Gambling, Otsuka Pharmaceutical Co More Abilify Lawsuit Stories Public Citizen Files Lawsuit To Get FDA to Add Impulse Control Warning Added To Requip, Similar Parkinson’s Disease Drugs May 6, 2019 Settlement for Abilify Gambling Cases To Be Reviewed With Parties and Judge This Week February 19, 2019 Trials for Six “Fast-Tracked” Abilify Gambling Cases Expected To Begin in Summer 2019 December 12, 2018 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (Posted: today) As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025. MORE ABOUT: BIOZORB LAWSUITCourt Clears BioZorb Lawsuit Design Defect Claims Over Recalled Breast Tissue Marker (03/26/2025)Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker (03/19/2025)Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (03/12/2025) Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: yesterday) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025) Cartiva SCI Lawsuit Alleges Toe Implant Worsened Pain, Decreased Range of Motion (Posted: 2 days ago) An Indiana woman has filed a Cartiva SCI implant lawsuit, indicating that the toe implant failed due to a defective design, resulting in the need for revision surgery and recommendations to permanently fuse her big toe. MORE ABOUT: CARTIVA IMPLANT LAWSUITCartiva Implant Injury Lawsuit Set for Trial in February 2026 (03/07/2025)Lawsuit Indicates Cartiva Implant Fails in 2 Out of 3 Patients, But Continued To Be Sold in U.S. (02/13/2025)Cartiva Toe Implant Lawsuit Filed Over Worsened Pain, Reduced Range of Motion and Need for Surgical Removal (02/07/2025)
Public Citizen Files Lawsuit To Get FDA to Add Impulse Control Warning Added To Requip, Similar Parkinson’s Disease Drugs May 6, 2019
Settlement for Abilify Gambling Cases To Be Reviewed With Parties and Judge This Week February 19, 2019
Trials for Six “Fast-Tracked” Abilify Gambling Cases Expected To Begin in Summer 2019 December 12, 2018
Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (Posted: today) As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025. MORE ABOUT: BIOZORB LAWSUITCourt Clears BioZorb Lawsuit Design Defect Claims Over Recalled Breast Tissue Marker (03/26/2025)Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker (03/19/2025)Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (03/12/2025)
Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: yesterday) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025)
Cartiva SCI Lawsuit Alleges Toe Implant Worsened Pain, Decreased Range of Motion (Posted: 2 days ago) An Indiana woman has filed a Cartiva SCI implant lawsuit, indicating that the toe implant failed due to a defective design, resulting in the need for revision surgery and recommendations to permanently fuse her big toe. MORE ABOUT: CARTIVA IMPLANT LAWSUITCartiva Implant Injury Lawsuit Set for Trial in February 2026 (03/07/2025)Lawsuit Indicates Cartiva Implant Fails in 2 Out of 3 Patients, But Continued To Be Sold in U.S. (02/13/2025)Cartiva Toe Implant Lawsuit Filed Over Worsened Pain, Reduced Range of Motion and Need for Surgical Removal (02/07/2025)